In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedicalCV Inc.

www.medcvinc.com

Latest From MedicalCV Inc.

Deals Update (05/2007)

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
Medical Device

AF Ablation: Progress & Promise

Tremendous progress has been made in the field of ablation therapy for atrial fibrillation (AF) over the past several years, and numerous device-based technologies to address this underserved and rapidly growing patient population are under clinical development. Minimally invasive, percutaneous AF ablation has evolved rapidly as well, although the procedure remains very challenging and limited to highly experienced centers.
Medical Device Innovation

NxStage: Bringing Dialysis Home

After years of steady growth, the dialysis market is predicted to increase dramatically, and this growth will severely strain the current system of dialysis clinics where most of these procedures are performed. Home hemodialysis could help relieve this bottleneck but has not been a viable alternative to date because of the lack of effective device innovation. NxStage Medical has developed a system that makes home hemodialysis a therapeutic option, which could dramatically improve both the health and lifestyle of patients, along with the economic future of the dialysis market.
Medical Device Reimbursement

Tapping the Potential of Atrial Fibrillation Devices

A solid foundation has been laid in the field of devices for atrial fibrillation; clinical trials have underscored the efficacy of cardiac ablation devices compared to drugs, reimbursement is in place for both surgical and catheter-based ablation procedures, and large companies have invested heavily in the technologies, validating the entire field. Early devices on the market are bringing in some revenues for their developers, but much remains to be done before atrial fibrillation becomes the multi-billion market everyone talks about. The biggest challenge that lies ahead: clinical trials, for today, all ablation devices are used off-label for atrial fibrillation.
Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Medical Devices
    • Laser
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • CV Dynamics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • MedicalCV Inc.
  • Senior Management
  • Marc P Flores, Pres. & CEO
    Michael A Brodeur, VP, Fin. & CFO
    Gary O Tegan, VP, Mktg.
    Adam L Berman, VP, R&D
  • Contact Info
  • MedicalCV Inc.
    Phone: (651) 452-3000
    9725 South Robert Trail
    Inver Grove Heights, MN 55077-4424
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register